A 55-year-old male presented with a diagnosis of metastatic urothelial carcinoma. He had undergone radical cystectomy with pelvic lymph node dissection followed by adjuvant chemotherapy. However, the disease progressed, with evidence of metastatic disease to the lungs and bones. Given the aggressive nature of the disease, a multi-agent chemotherapy regimen was initiated. This regimen included ifosfamide, a potent alkylating agent known for its efficacy in treating various solid tumors, including urothelial carcinoma. Which of the following is a common side effect associated with ifosfamide therapy?
